Matthew Burkett
Family · Uniontown, PANPI 1689654006
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 251 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Amgen at 36.2% of the total. 2025 is the largest year on record at $1,600, 2.3 times the $697 reported in 2021. Among family clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 251 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Lilly USA, LLC$480
- AbbVie$435
- ANI Pharmaceuticals, Inc.$392
- Novo Nordisk$349
- Alkermes, Inc.$122
- plus $979 from 21 others
What the payments were for
- Food & beverage$4,29899%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 85 | $1,562 |
| Lilly USA, LLC | 29 | $480 |
| AbbVie | 35 | $435 |
| ANI Pharmaceuticals, Inc. | 17 | $392 |
| Novo Nordisk | 24 | $349 |
| Alkermes, Inc. | 9 | $122 |
| Indivior Inc. | 4 | $94 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $91 |
| Novartis | 5 | $82 |
| Amarin Pharma, Inc. | 5 | $82 |
| Johnson & Johnson | 5 | $81 |
| Pfizer | 4 | $77 |
| Invivyd Inc | 3 | $65 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| Astellas Pharma US Inc | 2 | $42 |
| Dexcom, Inc. | 3 | $41 |
| AstraZeneca | 2 | $39 |
| Exact Sciences | 2 | $38 |
| GSK | 2 | $35 |
| Gilead | 1 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Boehringer Ingelheim | 1 | $26 |
| Bayer | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$241
How this compares
$4,321 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 97 | $109,058 |
| EliquisApixaban | 64 | $51,938 |
| XareltoRivaroxaban | 32 | $21,442 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $14,586 |
| OzempicSemaglutide | 13 | $14,096 |
| JanuviaSitagliptin Phosphate | 22 | $13,493 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $9,196 |
| KerendiaFinerenone | 11 | $7,593 |
| VascepaIcosapent Ethyl | 12 | $4,172 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $3,558 |
| Tamsulosin Hcl | 126 | $3,064 |
| Atorvastatin Calcium | 195 | $2,780 |
| Novolog FlexpenInsulin Aspart | 18 | $2,632 |
| Sucralfate | 28 | $2,609 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 37 | $2,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $480 | $109,05897 claims |
| PfizerEliquis | $77 | $51,93864 claims |
| Johnson & JohnsonXarelto | $81 | $21,44232 claims |
| Novo NordiskOzempic | $349 | $14,09613 claims |
| BayerKerendia | $21 | $7,59311 claims |
| AbbVieSynthroid | $435 | $1,42824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.
Other family in Uniontown
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
- Patricia HabdasPittsburgh$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.